Trial Profile
A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention With Adjuvant Nivolumab in Non-Small Cell Lung Cancer Participants With ctDNA-detected Minimal Residual Disease After Surgical Resection
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Paclitaxel; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CheckMate 9TN
- Sponsors Bristol-Myers Squibb
- 18 Jun 2020 This trial has been Discontinued in United kingdom according to European Clinical Trials Database record.
- 27 May 2020 Planned initiation date changed from 15 Jun 2020 to 15 Jan 2021.
- 27 May 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.